Companies Haemonetics

Haemonetics

Boston

Total Offices: 11

1,993 Total Employees

Year Founded: 1971

View Website

Haemonetics Company Growth, Stability & Outlook

Updated on September 08, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Haemonetics and has not been reviewed or approved by Haemonetics.

What's the stability & growth outlook for Haemonetics?

Strengths in profitability, cash generation, and leadership positions in plasma and viscoelastic testing are accompanied by reported revenue pressure and concentration and competitive challenges in select subsegments. Together, these dynamics suggest resilient underlying performance with improving earnings quality while headline growth remains constrained until transition and mix headwinds ease.

Key Insight for Candidates

Profitability-over-headline-growth tradeoff: Haemonetics is intentionally pruning lower-margin lines and navigating a major customer transition, producing choppy reported revenue but consistent organic growth, margin expansion and rising EPS/FCF. Candidates should expect stability driven by mix and cost discipline, with success measured on profitability and execution more than pure top-line.

Evidence in Action

Ex‑CSL Reporting Discipline — The CSL transitional supply agreement is excluded from core metrics, with FY2026 organic ex‑CSL growth guided at 8–10% and Q3 organic ex‑CSL growth of ~7.5%. Teams align to underlying demand signals, set goals independent of contract noise, and maintain confidence in growth execution.
Portfolio Pruning For Margins — The Whole Blood divestiture (Jan 14, 2025) and mix shift drove ~60% gross margin and ~26% operating margin, with FY2026 EPS guided to $4.90–$5.00 and FCF to $200–$220M. Employees prioritize higher‑margin lines and capital efficiency, reinforcing resilient earnings through cycles.

Positive Themes About Haemonetics

Profitability: Recent updates show margins and earnings per share improving, with full‑year guidance raised. Management commentary points to stronger operating performance across core Plasma and Blood Management technologies.
Healthy Cash Flow: Guidance indicates higher expected free cash flow and recent quarters delivered notably stronger cash generation. Working capital and margin improvements are contributing to this stability.
Strong Market Position & Advantage: Disclosures describe leadership in plasma collection and advanced viscoelastic testing, reinforced by a large installed base and ongoing product adoption. Strategic acquisitions and upcoming launches are intended to bolster this competitive position.

Considerations About Haemonetics

Stagnant Revenue: Guidance points to a year‑over‑year decline in total reported revenue and recent quarters showed reported contraction. Portfolio divestitures and a major customer transition are masking underlying growth.
Concentrated Customer Base: The impact from a large plasma customer transition highlights exposure to a few significant buyers. Extensions are non‑exclusive and contract shifts can quickly affect reported results.
Weak Market Position & Pricing Challenges: Interventional Technologies has been soft amid adoption shifts and strong incumbent competition, tempering Hospital segment performance. Planned product launches aim to reaccelerate growth, but near‑term momentum remains pressured.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

These insights are generated using AI and may not reflect internal data or verified company information. They are intended solely for general informational purposes and should not be considered a definitive assessment of the company’s reputation. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.